DNA topoisomerase II inhibitor, etoposide, induces p21WAF1/CIP1 through down-regulation of c-Myc in K562 cells

Anticancer Res. 2002 Nov-Dec;22(6C):3827-32.

Abstract

Background: Anticancer agents modulate gene expression and these changes are essential for tumor cell killing. To investigate the mechanism by which etoposide acts as an anticancer agent, the relationship between p21WAF1/CIP1 (p21) and c-Myc was studied.

Materials and methods: K562 cells with and without ectopic c-Myc expression were studied. Apoptosis was detected using propidium iodide and Hoechst 33342 double staining. The c-Myc and p21 levels were studied by RT-PCR and immunoblot. The p21 promoter (from -205 to +67) was investigated by the luciferase reporter gene assay.

Results: Ectopic c-Myc-expressing K562 (K562/c-Myc) cells showed more extensive apoptosis than K562 cells after continuous exposure to 200 microM etoposide for 24 hours. During this treatment, p21 expression was not observed in K562/c-Myc cells, and the expression of c-Myc and p21 was mutually exclusive. Etoposide activated the p21 promoter in a concentration-dependent manner, and etoposide-induced luciferase activity was suppressed by co-transfection of c-Myc.

Conclusion: p21 promoter activity was repressed by c-Myc in proliferating K562 cells, and detoposide-induced down-regulation of c-Myc released this suppression, resulting in the induction of p21.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Phytogenic / pharmacology*
  • Apoptosis / drug effects
  • Base Sequence
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclins / antagonists & inhibitors
  • Cyclins / biosynthesis*
  • Cyclins / genetics
  • Down-Regulation / drug effects
  • Enzyme Inhibitors / pharmacology*
  • Etoposide / pharmacology*
  • Gene Expression Regulation, Neoplastic / drug effects*
  • Genes, myc / drug effects
  • Genes, myc / genetics
  • Humans
  • K562 Cells / drug effects*
  • K562 Cells / metabolism
  • K562 Cells / physiology
  • Molecular Sequence Data
  • Promoter Regions, Genetic
  • Proto-Oncogene Proteins c-myc / biosynthesis*
  • Proto-Oncogene Proteins c-myc / genetics
  • Topoisomerase II Inhibitors*
  • Transcription, Genetic / drug effects

Substances

  • Antineoplastic Agents, Phytogenic
  • CDKN1A protein, human
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclins
  • Enzyme Inhibitors
  • Proto-Oncogene Proteins c-myc
  • Topoisomerase II Inhibitors
  • Etoposide